Clinicians can enhance patient understanding by using numerical data instead of verbal probabilities, consistent denominators, absolute risk comparisons, and clear context for unfamiliar data types. ja.ma/42JRNGk

📊 Largest real-world CDK4/6i study (P-VERIFY, n=9146) just published. ⏳ Median PFS: Palbo 22.7 mo, Ribo 22.9 mo, Abema 22.9 mo. ⚖️ No significant differences across the three drugs. esmoopen.com/article/S2059-…

🫁 Sequential therapy for advanced/metastatic #EGFRm #NSCLC 🫁 🫁 I’ve compiled it into a table. (PFS & OS only) 🌟 As of October 2025 🌟 I will update after #ESMO25 #lungcancer #nsclc #egfr #LCSM

Mary E. Brunkow yılda 30 makale basmadı (bizim memlekette bunu “araştırmacı olmak” sanan hâlâ var). Tüm bilimsel yaşamı boyunca sadece 34 makalesi var, h-index’i 21. Şu çok ünlü, “Stanford’un sözde en etkili bilim insanları” listesinde de yok. Ama yaptığı iş sağladığı fayda ve

Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy | Nature nature.com/articles/s4158…

#ESMO25 BEGONIA: Dato-DXd + Durvalumab as 1L in a/mTNBC 🔹 All-comer cohort: ORR 79%, mDoR 17.6 mo, mPFS 14 mo 🔹 PD-L1–high cohort: ORR 82% 💬 In line with ASCENT-03/04 and TROPION-Breast02, supporting chemo-free ADC+/-IO as a potential new 1L strategy in mTNBC

#ESMO25 💥DESTINY-Breast05 💥 T-DXd vs T-DM1 in residual high-risk HER2+ early BC: ✅️IDFS: 6.2 % vs 12.5 % → HR 0.47 ILD: 9.6 % (2 G5) vs 1.6 %! 💬 T-DXd substantially lowered recurrence risk vs T-DM1 — likely the new post-neoadjuvant standard. Full data eagerly awaited

#VIKTORIA1: combos of gedatolisib (multi target inhibitor of PI3 and mTOR 1/2) in PI3 wt post CDK 4/6 ER+ #bcsm PFS Fulv - 2.0 mo Fulv/ged - 7.4 mo Fulv/palbo/ged -9.3 mo *no OS #ESMO25 #ESMOAmbassadors

📌Excellent discussion by Sara Tolaney ✨ at Presidential Symposium I #ESMO25 “Reshaping Destiny: trasforming outcomes in high-risk HER2+ BC” DESTINY-Breast05 OncoAlert #OncoAlertAF Dana-Farber’s Breast Oncology Center

RCT on timing of pegfilgrastrim after CT shows significantly reduced bone pain with 72-hour timing as compared to 24- and 48-hour timing #ESMO25 ESMO - Eur. Oncology OncoAlert

🚨 #ESMO25 #mCRC – Phase II OPTIPRIME (FFCD 1605) explored a stop-and-go FOLFOX + panitumumab strategy in RAS/BRAF WT mCRC (n=115) 🎯 Median duration of disease control = 24.9 mo (90% CI 19.3–28.3) 💥ORR 74.8% at induction → 45% 1st reintro → 25% later reintros ▪️OS 36.1 mo

Summary of day 3 at #ESMO2025 🔺HORIZON-Breast01 🔹In previously treated HER2+ mBC, Trastuzumab Rezetecan showed PFS advantage vs pyrotinib + capecitabine ⏱️30.6 mo vs 8.3 mo ⚠️HR 0.22 📊ORR 82% vs 56% 📉low ILD (2.8%) 🔺ASCENT-03 🔹1L mTNBC ineligible for IO ✅SG imroves PFS

NICHE-2 absolutely delivers. Game over for chemo in dMMR colon cancer 💥🧬 In locally advanced dMMR colon cancer, FOxTROT already showed us chemo doesn’t work, and now NICHE-2 makes it undeniable. 💊 Neoadjuvant nivolumab + ipilimumab → • 99% pathologic response • 67%

Important data from #SONIA trial – #ESMO25 Day 4 ❗️No OS benefit for 1L vs 2L CDK4/6i in HR+/HER2– advanced BC. ❗️Post-hoc suggests OS benefit for #premenopausal pts (HR 0.53). ❗️My opinion: For many #postmenopausal pts with low disease burden, starting with single-agent AI

🚨#ESMO25 #Cholangiocarcinoma –Phase 2–3 ZSAB-neoGOLP trial (Toripalimab + Lenvatinib + GEMOX) in resectable high-risk iCCA 🎯 mEFS 18.0 vs 8.7 mo 💥 ORR 54.4% | MPR 19.3% | pCR 4.5% ✨ OS trend favoring neoadjuvant arm (NE vs 31.4 mo) A strong neoadjuvant signal! Sometimes the

🫁 #ESMO25 #NSCLC – Updated phase III ALINA trial: adjuvant alectinib vs chemo in resected ALK+ NSCLC (stage IB–IIIA) 🎯 DFS HR 0.24 (95% CI 0.13–0.43, p<0.0001) || 4-year follow-up: DFS 75.5% vs 47.0% 💥 CNS-DFS HR 0.37 (95% CI 0.19–0.74) ☄️ OS trend HR 0.40 (95% CI 0.12–1.32)

🫁 #ESMO25 #NSCLC – Phase II IFCT-2003 ALBATROS: lorlatinib in advanced ROS1+ NSCLC after 1L ROS1-TKI failure! 🎯 ORR 30% (INV) / 34% (BICR) 💥 mPFS 7.4 mo (95% CI 4.1–14.6) || mDOR 20.4 mo ✨ mOS 42.3 mo, 12-mo OS 77.3% Though this ALBATROS flies low, it’s far from crashing🕊️

Another great metastatic prostate cancer "landscape" figure from Ana Aparicio during her aggressive variant prostate cancer talk at #ESMO25 Approved, and "likely to be approved"/new data (bottom), treatment options UroToday.com

#ESMO25 Managing HR+/HER2– mBC in 2025 💬An update is likely following the evERA and VIKTORIA-1 trials From Dr. William Gradishar's presentation👇